According to a new market report published by Lucintel, the future of the carcinoembryonic antigen market (CEA) looks promising with opportunities in colorectal cancer, pancreatic cancer, ovarian cancer, breast cancer, and thyroid cancer. The global carcinoembryonic antigen market is expected to grow with a CAGR of 11% from 2020 to 2025. The major drivers for this market are increasing prevalence of chronic diseases and growing demand for minimally invasive diagnostic procedures in cancer.
To download report brochure, please go to https://www.lucintel.com/carcinoembryonic-antigen-market.aspx and click "download brochure" tab from the menu
The carcinoembryonic antigen is the recurrent indicator in asymptomatic patients and presently the most cost-effective assessment for preclinical detection of illness. The test is beneficial for the primary detection of liver metastasis in patients with diagnosed colorectal cancer. In this market, colorectal cancer, pancreatic cancer, ovarian cancer, breast cancer, and thyroid cancer are the major application segments. Lucintel forecasts that colorectal cancer will remain the largest application segment over the forecast period due to increasing demand for minimally invasive diagnostic procedures, growing geriatric population base, and the increasing prevalence of unhealthy lifestyles, such as irregular dietary habits and exposure to carcinogenic elements.
Within this market, hospitals will remain the largest end user segment over the forecast period due to the presence of favorable government initiatives pertaining to cancer awareness and control by organizations, such as the Cancer Prevention and Control Research Network (CPCRN) and the National Cancer Institute.
North America will remain the largest region over the forecast period due to high incidence rates of cancers, presence of sophisticated healthcare infrastructure, and high patient awareness levels coupled with relatively higher healthcare expenditure levels in the region.
Roche, Quest Diagnostics, GenWay Biotech, Correlogic Systems, Creative Diagnostics, Omega Diagnostics Group, RayBiotech, and Boster Biological Technology are among the major suppliers in the global carcinoembryonic antigen market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global carcinoembryonic antigen market by application, end user, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Carcinoembryonic Antigen Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global carcinoembryonic antigen market by application, end user, and region as follows:
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Breast Cancer
Thyroid Cancer
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals
Diagnostic Centers
Cancer Centers
Research Centers
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Spain
Germany
France
This more than 150 page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.